Restoring Biological Harmony for Patients with Debilitating Disease

We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.

Learn More

DEVELOPMENT PROGRAMS

Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.

Learn More

Recent Press Releases

February 20, 2020: miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020
February 7, 2020: miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
February 6, 2020: miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
January 30, 2020: miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
January 23, 2020: miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences

View All